Why Most Gene Expression Signatures of Tumors Have Not Been Useful in the Clinic

Breast cancer provides a ripe arena for an analysis of why gene signatures devised from microarray data have failed to fulfill their promise. Omics technologies are expected to enhance our understanding of a variety of diseases and to open the door to patient-specific personalized medicine. Despite the extensive literature on the use of gene expression arrays to predict prognosis in cancer patients, poor progress has been made in the translation of gene expression signatures for use in the clinics. Breast cancer provides a ripe arena for an analysis of why such signatures have failed to fulfill their promise.

[1]  Ronald W. Davis,et al.  Quantitative Monitoring of Gene Expression Patterns with a Complementary DNA Microarray , 1995, Science.

[2]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[3]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[4]  Van,et al.  A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.

[5]  D. Ransohoff.  Rules of evidence for cancer molecular-marker discovery and validation , 2004, Nature Reviews Cancer.

[6]  Stefan Michiels,et al.  Prediction of cancer outcome with microarrays: a multiple random validation strategy , 2005, The Lancet.

[7]  D. Holdstock.  Past, present--and future? , 2005, Medicine, conflict, and survival.

[8]  Zhiyuan Hu,et al.  Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay , 2006, Breast Cancer Research.

[9]  J. Sparano,et al.  TAILORx: trial assigning individualized options for treatment (Rx). , 2006, Clinical breast cancer.

[10]  A. Nobel,et al.  The molecular portraits of breast tumors are conserved across microarray platforms , 2006, BMC Genomics.

[11]  A. Nobel,et al.  Concordance among Gene-Expression – Based Predictors for Breast Cancer , 2011 .

[12]  Marc Buyse,et al.  Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial , 2006, Nature Clinical Practice Oncology.

[13]  L. V. van't Veer,et al.  Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. , 2006, Journal of the National Cancer Institute.

[14]  C. Sotiriou,et al.  Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? , 2007, Nature Reviews Cancer.

[15]  A. Dupuy,et al.  Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. , 2007, Journal of the National Cancer Institute.

[16]  C. Sotiriou,et al.  Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures , 2007, Breast Cancer Research.

[17]  Benjamin Haibe-Kains,et al.  A comparative study of survival models for breast cancer prognostication based on microarray data: does a single gene beat them all? , 2008, Bioinform..

[18]  Heidi Ledford,et al.  The death of microarrays? , 2008, Nature.

[19]  S. Koscielny.  Critical review of microarray-based prognostic tests and trials in breast cancer , 2008, Current opinion in obstetrics & gynecology.

[20]  A. Nobel,et al.  Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  B. De Moor,et al.  Prediction of cancer outcome using DNA microarray technology: past, present and future. , 2009, Expert opinion on medical diagnostics.

[22]  1332 The distribution of recurrence scores in Europe and Middle East (EME) compared with the US , 2009 .